RPAP2: A Potential Drug Target and Biomarker for Diseases (G79871)

Target Name: RPAP2

NCBI ID: G79871

RPAP2

RPAP2: A Potential Drug Target and Biomarker for Diseases

RPAP2 (C1orf82) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the RNA-protein fusion family, which includes proteins such ashnRNA, mRNA, and rRNA.RPAP2 is characterized by a N- terminal domain that is composed of a helix and a loop, as well as a C- terminal domain that is composed of a series of coiled coils.

RPAP2 is involved in the regulation of gene expression in various cell types. It has been shown to play a role in the regulation of stem cell proliferation and differentiation, as well as in the regulation of tissue repair and regeneration. It is also involved in the regulation of the immune response and in the regulation of cell signaling pathways that are involved in inflammation and infection.

RPAP2 is a potential drug target for a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. Several studies have suggested that RPAP2 may be a useful biomarker for monitoring the effectiveness of certain treatments, such as cancer chemotherapy.

One of the main challenges in studying RPAP2 is its highly conserved nature. There are many different isoforms of RPAP2 that are found in various tissues of the body, and it can be difficult to differentiate between them. Additionally, the functions of RPAP2 in different cell types are highly conserved, making it difficult to identify the specific functions of RPAP2 in any given cell type.

Despite these challenges, research into RPAP2 is ongoing and has led to several new findings about its functions and potential as a drug target. One of the most significant findings is that RPAP2 is involved in the regulation of microRNA (miRNA) expression. miRNA are small non-coding RNAs that play a critical role in post-transcriptional gene regulation, and they are involved in the regulation of a wide range of cellular processes, including cell growth, apoptosis, and inflammation.

Studies have shown that RPAP2 is a negative regulator of miRNA expression, which means that it works to reduce the levels of miRNA in cells. This is important because miRNA plays a critical role in the regulation of cellular processes that are involved in cancer, and because the levels of miRNA are often reduced in cancer cells.

Another potential drug target for RPAP2 is its role in the regulation of cellular signaling pathways. RPAP2 has been shown to be involved in the regulation of several signaling pathways that are involved in inflammation and infection, including the T-cell signaling pathway and the NF-kappa-B signaling pathway. These signaling pathways are important for the regulation of cellular processes that are involved in immune response, inflammation, and infection.

RPAP2 is also involved in the regulation of stem cell proliferation and differentiation. Stem cells are a type of cell that have the ability to develop into any type of cell in the body, and they are a key factor in the development and treatment of many diseases. RPAP2 has been shown to play a role in the regulation of stem cell proliferation and differentiation, and it is possible that it may be a useful target for the treatment of certain stem cell-based therapies.

In addition to its potential as a drug target, RPAP2 is also a potential biomarker for a variety of diseases. Because RPAP2 is highly conserved and is involved in the regulation of multiple cellular processes, it is possible that it may be a useful indicator of the effectiveness of certain treatments. For example, studies have suggested that RPAP2 may be a useful biomarker for monitoring the effectiveness of cancer chemotherapy.

Overall, RPAP2 is a protein that is expressed in various tissues of the body and is involved in the regulation of gene expression

Protein Name: RNA Polymerase II Associated Protein 2

Functions: Protein phosphatase that displays CTD phosphatase activity and regulates transcription of snRNA genes. Recognizes and binds phosphorylated 'Ser-7' of the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit POLR2A, and mediates dephosphorylation of 'Ser-5' of the CTD, thereby promoting transcription of snRNA genes (PubMed:17643375, PubMed:22137580, PubMed:24997600). Downstream of EIF2AK3/PERK, dephosphorylates ERN1, a sensor for the endoplasmic reticulum unfolded protein response (UPR), to abort failed ER-stress adaptation and trigger apoptosis (PubMed:30118681)

The "RPAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets